Clinical Trial Update: Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the pharmacokinetics of twice-daily or once-daily DTG (50 mg) in children with HIV and tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• DTG (dolutegravir)

Snippet

Sponsor: University of KwaZulu | Conditions: Tuberculosis, Hiv | Phase 4 | Status: UNKNOWN